Four Pillars to Achieve Patient Centricity

Lisa Bance, PharmD, Kristyn Feldman, PhD, Venkat Sethuraman, PhD, Aaron Mitchell

> Download

Truly patient-centric clinical trials enable sponsors to more directly and methodically align the objectives of a clinical trial to the true needs of patients, and can result in more meaningful endpoints, an up-front understanding of operational issues, enhanced patient recruitment and patient retention, and better support for participating sites. But the strategies and skills necessary to design and execute successful, patient-centric clinical trials in this dynamic environment must keep pace with the changing landscape of empowered patients, drug development and healthcare.

Based on our extensive experience and original research conducted with clinical trial participants and pharmaceutical executives, we created a framework to address the evolving concept of patient-centric clinical trials. These four pillars of patient centricity adapt to different phases of development, allow organizations to apply patient-centric strategic thinking to their trials, and provide guidelines to develop processes that would lead to a successful trial design or refine their efforts to move to the next level of patient centricity.

In this article, ZS experts share:

  • The four pillars of patient-centric drug development
  • How life sciences companies can improve clinical trials—and the patient experience—with patient centricity
  • Key principles of patient-centric strategic thinking

About the Experts

Lisa Bance leads life cycle evidence strategy within ZS’s R&D excellence practice. Lisa works with pharmaceutical clients to drive evidence-based strategy, design, analytics and insights from early commercialization to product maturity.

Kristyn Feldman is an associate consultant within the R&D excellence practice. Kristyn’s work focuses on patient centric drug development by leveraging her background in clinical research to define and develop a growing suite of innovative products and consulting services for R&D clients.

Venkat Sethuraman is the global clinical lead within ZS's R&D excellence practice. Venkat has nearly 20 years of experience in R&D drug development lifecycle with deep expertise in biostatistics, clinical trial design strategy, clinical trial optimization, and regulatory approvals.

Aaron Mitchell is a managing principal and the global lead for ZS’s R&D excellence practice. Aaron partners with clients to strengthen the value of their pipelines, optimize the execution of clinical trials, drive effective use of real-world evidence and improve medical and scientific engagement.